Generics reduce costs and increase access

Home/Reports | Posted 08/01/2016 post-comment0 Post your comment

Generics reduce costs for both patients and payers and increase patient’s access to medicines, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

60 MD002436

The health economics study, which was initiated by the European Generic and Biosimilar Medicines Association (EGA) and the German Generic and Biosimilar Medicines Association (Progenerika), shows the value and contribution of generics to society. It focusses on three key therapeutic areas: hypertension, breast cancer and depression.

The report, which was released on 16 November 2015, shows that generics improve adherence for patients, while also showing that generics competition increases the cost-effectiveness of therapy, thereby enabling physicians to treat more patients. Generics competition also enables doctors to improve quality-adjusted life-years (QALYs) by reducing their cost (from around Euros 50,000 to Euros 7,200).

In light of the findings of the report Adrian van den Hoven, EGA Director General, said that ‘policy makers should do more to stimulate competition for generic medicines which, as the IGES Study shows, are the main driver of access’.

In the following series of five articles some of the results of the report discussing how generics can reduce costs and increase access to medicines are presented in more detail.

Related articles

Impact of antidepressant generics in Europe

Impact of breast cancer generics in Europe

Impact of hypertension generics in Europe

Impact of generics on European budgets

Generics market share in Europe

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010